Observational studyThe European respiratory journal2025
Phenotyping the responses to systemic corticosteroids in the management of asthma attacks (PRISMA).
Observational study in The European respiratory journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Symptom burden to characterise, predict, and prevent asthma attacks: a patient-level meta-analysis of randomised trials and translational prospective studies.The Lancet. Respiratory medicine · 2026Pooled it
- Impact of Sex on Prediction of Asthma Attacks by Clinical Risk Factors and Type 2 Biomarkers.Chest · 2026Pooled it
- Inflammatory and clinical risk factors for asthma attacks (ORACLE2): a patient-level meta-analysis of control groups of 22 randomised trials.The Lancet. Respiratory medicine · 2025Pooled it
- Trial
- Phenotyping treatment-naive uncontrolled asthma in adults: A primary care framework.The journal of allergy and clinical immunology. Global · 2026Article
- Effects of T2-high asthma heterogeneity and inhaled corticosteroid on airway and metabolic profiles: A multi-omic approach.Journal of translational internal medicine · 2026Article
- Severe Asthma Exacerbations: From Risk Factors to Precision Management Strategies.Journal of clinical medicine · 2026Review
- Asthma and corticosteroids "Frontiers in allergy · 2026Review
- Integrating blood eosinophils and exhaled nitric oxide (FeNO) in asthma diagnostic pathways for adults and children: the PROPULSION SANTÉ observational study with translational sub-studies (DIVE, DIVE2)-protocols.BMJ open respiratory research · 2025Article
- Fractional exhaled nitric oxide and the response to prednisolone for asthma attacks in patients treated with anti-IL5/5Rα therapy: a prospective observational study.The European respiratory journal · 2025Article
- Single-Cell Transcriptomic Profiling Reveals a Distinct Monocyte MIF/ANXA1 Signature Associated With Poor Responsiveness to ICS.Allergy, asthma & immunology research · 2025Article
- Baseline Membrane Thickness in Asthma: Where Type-2 Inflammation Meets Remodeling?American journal of respiratory and critical care medicine · 2025Article
- Review
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAsthma attacks are heterogeneous. It is not known whether the response to oral corticosteroids (OCS) in acute asthma varies according to type 2 (T2) inflammatory biomarkers, blood eosinophil count (BEC) and fractional exhaled nitric oxide (
methodsWe conducted a longitudinal observational study of people experiencing an asthma attack evaluated before and after a 7-day OCS course. The primary outcome was post-bronchodilator change in forced expiratory volume in 1 s (FEV
results53 people were enrolled, with 16 (30%) T2-Low/Low, 27 (51%) T2-Mid and 10 (19%) T2-High/High asthma attacks. Post-bronchodilator FEV
conclusionsWe found that objective improvement following OCS is confined to T2-High events. As in chronic asthma, greater T2 burden identifies a distinct clinical and therapeutic trajectory, whereas OCS‑related adverse events are uniformly distributed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.